LURASIDONE: A REVIEW OF ANALYTICAL METHODS FOR ESTIMATION IN PHARMACEUTICAL FORMULATIONAbstract
Lurasidone is an atypical antipsychotic approved by the FDA for the treatment of schizophrenic disorder and depressive episodes linked through bipolar I disorder in adults when used exclusively or in combination with lithium or valproate. Lurasidone is a benzisothiazole antipsychotic, an antagonist at D2, 5-HT2A and 5-HT7 receptors and a partial agonist at 5-HT1A receptors. As with other antipsychotics, the exact mechanism of action of lurasidone is unknown, although its effects in schizophrenia are supposed to be related to D2 and 5-HT2A receptor antagonism. This work includes published analytical methods so far reported in the literature, for estimation of lurasidone in biological samples and pharmaceutical formulations. Techniques like UV – Visible Spectrophotometry, high – performance liquid – chromatography (HPLC), high – performance thin – layer chromatography (HPTLC), and Liquid chromatography-mass spectroscopy (LC-MS) with ESI has been used for analysis, from which it can be witnessed that high-performance liquid chromatography methods have been applied most expansively.
Z. G. Khan, S. B. Bari and D. D. Patil
Department of Pharmaceutical Chemistry, H. R. Patel Institute of Pharmaceutical Education & Research, Shirpur, Dhule, Maharashtra, India.
08 January 2016
23 February 2016
25 February 2016
29 February 2016